Vergroten van de voetafdruk en uitbreiden van therapeutische expertise om sponsoren door de levenscyclus van klinische ontwikkeling te leiden

SOUTHBOROUGH, Mass. – (BUSINESS WIRE) – Veristat, een full-service CRO, heeft vandaag aangekondigd dat het de acquisitie heeft voltooid van The Clinical Trial Company Ltd. (TCTC Group), een wereldwijdeContract Research Organizationmet een hoofdkantoor in Europa. TCTC Group biedt klinische operaties, regelgevende, personeels- en medische diensten voor full-service klinische onderzoeken en zelfstandige klinische onderzoeken voor biofarmaceutische bedrijven over de hele wereld.

De acquisitie van TCTC Group maakt gebruik van complementaire sterke punten en biedt extra schaal om superieure, ultramoderne benaderingen te bieden om risico’s te beperken en zinvolle resultaten te bereiken voor sponsors en hun patiënten over de hele wereld. TCTC Group levert een schat aan ervaring op in gen- en celtherapie, proeven op het CNS en zeldzame ziekte; het leveren van hoogwaardige klinische onderzoeksdiensten aan bedrijven die op deze gebieden actief zijn. Bovendien brengt TCTC Group kennis en ervaring in het adviseren van cliënten over proefstrategieën in geavanceerde therapieën. TCTC Group heeft met succes proeven uitgevoerd voor de eerste gentherapie die in Europa is goedgekeurd en die de norm is voor andere gentherapieën in ontwikkeling.

Veristat Strengthens Its European Presence with the Acquisition of The Clinical Trial Company Ltd.

Increasing Its Footprint and Expanding Therapeutic Expertise to Guide Sponsors Throughout the Clinical Development Lifecycle

SOUTHBOROUGH, Mass.–(BUSINESS WIRE)– Veristat, a full-service CRO, announced today that it has completed the acquisition of The Clinical Trial Company Ltd. (TCTC Group), a global Contract Research Organization headquartered in Europe. TCTC Group provides clinical operations, regulatory, personnel and medical services for full-service clinical studies and stand-alone clinical trials for biopharmaceutical companies throughout the world.

The acquisition of TCTC Group harnesses complementary strengths and provides added scale to deliver superior, state-of-the-art approaches to mitigate risk and achieve meaningful outcomes for sponsors and their patients around the globe. TCTC Group contributes a wealth of experience in gene and cell therapy, CNS and orphan disease trials; providing high-quality clinical research services to companies operating in these areas. Additionally, TCTC Group brings knowledge and experience in advising clients on trial strategies in advanced therapies. TCTC Group successfully executed trials for the first gene therapy approved in Europe setting the standard for other gene therapies in development.

“With the addition of TCTC Group, Veristat has gained a highly skilled team of experts to support our clients worldwide,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Providing superior clinical services with our expanded team will enable us to better manage, recruit and run our clients’ trials on a global scale. In recent years the industry has seen increased funding in CNS and gene therapy research. With the addition of the TCTC team, Veristat has bolstered our resources in this critical therapeutic category and obtained a leader in Advanced Therapy Clinical Trials.”

The TCTC Group brings 17 years of European expertise in project management and clinical operations to Veristat. As part of the acquisition, Veristat will be retaining the seasoned staff of clinical experts and contractors that TCTC Group has cultivated. Ewan Campbell, co-founder and former Director of TCTC Group, will stay on to provide his experience and expertise to our joint clients. Ewan has worked in the industry 20+ years for many leading pharmaceutical companies including Merck Serono, Genzyme and Abbott. He has also been involved with two start-up biotech companies, both of which floated on the LSE.

“The team at TCTC Group are delighted to be part of Veristat,” stated Ewan Campbell, co-founder and former Director of TCTC Group. “The acquisition by Veristat enhances our capabilities across all our services to proactively address the increased demand from sponsors. The combined people and service strengths will make Veristat the CRO of choice for small and medium biopharmaceutical companies who need assistance in bringing complex and novel therapies to patients worldwide.”

About Veristat

Veristat is a scientifically oriented and impactful full-service clinical research organization (CRO) that is committed to partnering with pharmaceutical, biotechnology, and medical device firms to advance their therapies throughout the entire clinical development and regulatory submission process. Veristat helps clients solve the unique and complex challenges that arise when trying to accelerate therapies along the development pathway to successful regulatory approval, beginning with study design, protocol development, site selection, and start-up through to clinical monitoring, data collection, analysis, and reporting. Veristat provides experience-based strategic decision-making, the operational efficiencies to manage and monitor international trials, the biometrics expertise to collect, analyse, and report clinical trial data to various regulatory agencies, and the therapeutic and medical proficiency in overseeing the entire process. Ultimately, we guide our clients to market success so that their therapies become available to improve and save people’s lives. For more information, visit http://www.veristat.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005115/en/

Contacts

Veristat:
Gillian Dellacioppa, Marketing Director

marketing@veristat.com or +1 508-429-7340